3 Biotech Stocks Ripping Higher This Morning

ARNA gaps higher after upbeat drug data, while NDA news sends OCUL and FOLD into rally mode

Managing Editor
Jul 11, 2017 at 10:27 AM
facebook twitter linkedin

U.S. stocks are mixed this morning, as the energy sector drags down broader markets. Among specific stocks on the move today are a trio of biotechs: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Ocular Therapeutix Inc (NASDAQ:OCUL), and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Here's a quick look at what's moving shares of FOLD, OCUL, and ARNA.

FDA Clearance Sends Amicus Stock To New Highs

Amicus Therapeutics stock is up 25% to trade at $12.94 -- and earlier hit a new 22-month high of $13.09 -- after scoring Food and Drug Administration (FDA) clearance to submit a new drug application (NDA) for its Fabry disease drug. It's been a banner year for FOLD stock, which has more than doubled from its Dec. 30 close at $4.97. 

Despite the strong price action, there are still plenty of bears betting against Amicus stock. Short interest accounts for more than a quarter of FOLD's total available float -- representing more than 18 times the equity's average daily trading volume.

OCUL's NDA Amendment Reverses Some Recent Losses

Ocular Therapeutix stock is up 22% to trade at $7.93, after the company amended the NDA for its DEXTENZA eye drug and requested an extension on the application's target action date. The amendment addresses a manufacturing equipment change that OCUL says addresses "outstanding issues" flagged by the FDA. Today's pop comes on the heels of a rough stretch for OCUL stock, which shed nearly one-third of its value over the previous two sessions.

In light of the recently wild price action, it's getting very expensive to bet on Ocular stock's short-term direction. Specifically, OCUL's Schaeffer's Volatility Index (SVI) of 298% arrives in the 100th percentile of its annual range, indicating that front-month options are pricing in extremely high volatility expectations.

Upbeat Trial Data Sparks Bull Gap for Arena Stock

Arena Pharmaceuticals stock is up a whopping 49% to trade at $27.40, fresh off a new annual high of $27.78, after its pulmonary arterial hypertension drug ralinepag met the primary goal of a mid-stage study. ARNA spent most of this year range-bound below resistance at its 50-week moving average, but its positive momentum has accelerated since the stock closed above this trendline in late June. Thanks to today's bull gap, the shares are now up 93% year-to-date.

Arena shares are quite likely benefiting from a short squeeze today. Short interest represents more than 26% of the equity's total available float, and it would take nearly a week to cover all of these bearish bets at ARNA's average daily trading volume.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1